Home About us Editorial board Ahead of print Current issue Archives Submit article Guidelines Contacts Login 
ISSN: Print -2349-0977, Online - 2349-4387
CHECK AND CHECKMATE - THE NEW MOLECULAR CHESS
Year : 2017  |  Volume : 4  |  Issue : 2  |  Page : 108-110

Bedaquiline and delamanid: Sharing the indian experience


Department of Respiratory Medicine, PD Hinduja National Hospital and Medical Research Center, Mumbai, Maharashtra, India

Correspondence Address:
Zarir F Udwadia
Department of Respiratory Medicine, PD Hinduja National Hospital and Medical Research Centre, Veer Savarkar Marg, Mahim, Mumbai - 400 016, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/astrocyte.astrocyte_73_17

Rights and Permissions

Currently, India is home to the highest number of multi-drug resistant tuberculosis (MDR-TB) patients in the world. Until now, MDR-TB was being treated with repurposed drugs which are toxic and are required to be given for up to 2 years. Two new oral anti-TB drugs, bedaquiline and delamanid have received approval in 2012 and 2014 respectively. While presenting the pharmacology, evidence of efficacy, WHO recommendations, current status of access as well as future directions regarding these two novel anti-TB agents, this paper delves into the India narrative recounting the short clinical experience thus far.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed699    
    Printed17    
    Emailed0    
    PDF Downloaded194    
    Comments [Add]    

Recommend this journal